Frontlight ResearchEarly access
CompletedNo phase
Autoimmune Basis for Postural Tachycardia Syndrome
Key facts
- Who runs it
- University of Oklahoma
- Where
- Oklahoma City, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 80 people enrolled
- Started
- 14 Jan 2022
- Ended
- 15 Jul 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Vagal stimulation
- Sham stimulation
- Record updated
- 29 July 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- 18-80 years old, female or male
- Either healthy control or individual with postural tachycardia syndrome (POTS) defined as heart rate increase >30 bpm from supine within 10 min of standing, in the absence of orthostatic hypotension (>20/10 mmHg fall in blood pressure), with chronic symptoms (>6 months), and in the absence of other acute cause of orthostatic tachycardia
- Able and willing to provide informed consent
- Understand and be able to comply with the study procedures and restrictions
Who cannot take part
- Hypertension (>150 mmHg systolic and >100 mmHg diastolic) based on history or findings at screening
- Cardiovascular disease, such as myocardial infarction within 6 months
- History or presence of significant immunological or hematological disorders
- History of vagotomy
- Patients with active implants (such as a cardiac pacemaker, or a cochlear implant); Healthy control subjects will be healthy, non-smoking and on no chronic medications at the time of the study. Healthy control subjects will be group-matched to the POTS patients for age and gender
- Orthostatic hypotension (consistent drop in blood pressure >20/10 mmHg with 10 min of standing)
- Currently pregnant women or women planning on becoming pregnant ≤ 3 months
- Inability to comply with the protocol
Where in United States
- Oklahoma Clinical and Translational Science InstituteOklahoma City, United States
About the trial
What the trial wants to find out
The purpose of this study is to test the hypothesis that an antibody-mediated autoimmune reaction will cause symptoms of autonomic dysfunction in some patients with postural tachycardia syndrome (POTS). The investigators further hypothesize that electrical stimulation of the vagus nerve will improve POTS symptoms, autoimmunity and inflammation.
The 2 groups in the trial
- Vagal stimulationExisting treatment, for comparison
Vagal stimulation will be given at 20 Hz for 1 hour daily with the bipolar electrode attached to the tragus for 2 months.
- Sham stimulationSham treatment, for comparison
Sham stimulation will be given at 20 Hz for 1 hour daily with the bipolar electrode attached to the earlobe for 2 months.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Noninvasive Vagus Nerve Stimulation in Postural Tachycardia Syndrome: A Randomized Clinical Trial.JACC. Clinical electrophysiology, 2024
- Record updated
- 29 July 2026